Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 278,231
  • Shares Outstanding, K 167,609
  • Annual Sales, $ 44,510 K
  • Annual Income, $ -70,480 K
  • 60-Month Beta 1.35
  • Price/Sales 6.25
  • Price/Cash Flow N/A
  • Price/Book 3.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.13
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.15
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.60 +3.75%
on 10/10/19
1.94 -14.43%
on 10/01/19
-0.17 (-9.29%)
since 09/11/19
3-Month
1.60 +3.75%
on 10/10/19
2.57 -35.41%
on 07/16/19
-0.87 (-34.39%)
since 07/11/19
52-Week
1.60 +3.75%
on 10/10/19
3.29 -49.54%
on 11/07/18
-1.44 (-46.45%)
since 10/11/18

Most Recent Stories

More News
Rigel Secures Credit Facility for Up to $60 Million

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a $60 million term loan credit facility with MidCap Financial ("MidCap"). At closing, $10 million was funded to Rigel...

RIGL : 1.66 (unch)
APO : 38.72 (-0.54%)
Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ("Kissei"), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate...

RIGL : 1.66 (unch)
Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to participate in a panel discussion at Citi's 14th Annual...

RIGL : 1.66 (unch)
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 14.29% and 12.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

RIGL : 1.66 (unch)
Rigel: 2Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $20.6 million in its second quarter.

RIGL : 1.66 (unch)
Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the second quarter ended June 30, 2019, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the...

RIGL : 1.66 (unch)
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

RIGL : 1.66 (unch)
JAZZ : 118.67 (+0.60%)
ETON : 6.20 (+4.73%)
BHC : 20.62 (+6.95%)
Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.

BAYRY : 17.9000 (+1.44%)
REGN : 300.77 (+0.81%)
JAZZ : 118.67 (+0.60%)
RIGL : 1.66 (unch)
Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2019 financial results after market close on Tuesday, August 6, 2019. Rigel senior management will follow...

RIGL : 1.66 (unch)
Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Rigel Pharmaceuticals, Inc. (RIGL) has been struggling lately, but the selling pressure may be coming to an end soon.

RIGL : 1.66 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade RIGL with:

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

2nd Resistance Point 1.75
1st Resistance Point 1.70
Last Price 1.66
1st Support Level 1.63
2nd Support Level 1.61

See More

52-Week High 3.29
Fibonacci 61.8% 2.64
Fibonacci 50% 2.44
Fibonacci 38.2% 2.25
Last Price 1.66
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar